Clinical trials: IOP
Glaucoma
A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention
A. To evaluate the ocular hypotensive efficacy of the rho-kinase Inhibitor (AR-12286 0.5% and 0.7%) ophthalmic solutions in open-angle glaucoma patients with uncontrolled IOP who are facing surgical intervention.
- Trial name
- NCT02174991
- Testing
- Rho-Kinase Inhibitor (AR-12286)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- New York Glaucoma Research Institute
Post-Injection Intraocular Pressure Spikes
Pre-Administration of Brimonidine in Intravitreal Anti-VEGF Therapy
In this study, investigators will be examining the intraocular pressure lowering effect of brimonidine 0.15% when administered 20min prior to intravitreal anti-VEGF injection.
- Trial name
- NCT03513172
- Testing
- topical brimonidine tartrate 0.15% (Alphagan® P; Allergan, Inc)
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Glaucoma
Results of Mass Switch From Latanoprost to Travoprost
Prostaglandin analogs are a leading class of glaucoma drugs with a proven safety and efficacy for controlling IOP. They include latanoprost, bimatoprost, travoprost and unoprostone.
- Trial name
- NCT00347126
- Where
- Singapore
- Volunteers
- 372 people
- Sponsor
- Singapore National Eye Centre